List view / Grid view
16 June 2011 | By Abbott
Reata and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes...
16 June 2011 | By AstraZeneca
AstraZeneca plans to establish a Predictive Science Centre in St. Petersburg...
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
15 June 2011 | By Pfizer
Pfizer Injectables, announced the addition of doxorubicin hydrochloride injection, USP...
14 June 2011 | By kdm communications limited
Technical Communities to distribute Tecan’s liquid handling platforms...
14 June 2011 | By Zyme Communications Ltd
Horizon Discovery has announced that it has successfully completed an eighteen month pilot program with Novartis...
14 June 2011 | By Abbott
The U.S. FDA approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat EPI due to cystic fibrosis...
14 June 2011 | By GlaxoSmithKline
GSK to acquire the remaining 51% equity interest of Shenzhen Neptunus...
13 June 2011 | By Corning Incorporated
Corning Inc., has hired Dr. Richard Eglen, as vice president and general manager of the Corning Life Sciences business segment...
13 June 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. is pleased to announce that Kevin Young, has been appointed a Commander of The British Empire...
13 June 2011 | By Merck
Merck and Hanwha Chemical Corporation to develop and commercialize a candidate biosimilar form of Enbrel® (etanercept)....
13 June 2011 | By GlaxoSmithKline
GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced that the FDA has approved Potiga™ (ezogabine) Tablets...
10 June 2011 | By H. Lundbeck A/S
H. Lundbeck A/S announced that Stig Løkke Pedersen, EVP for Commercial Operations, has decided to resign from his position at Lundbeck in order to pursue new opportunities...
10 June 2011 | By Novartis
New data from a pivotal study in more than 1,800 infants...
